BELMONT, Calif. and BEIJING, Sept. 1 /Xinhua-PRNewswire/ -- CapitalBio Corporation, a leader in biochip technology and applications, today announced that it has been named one of the Red Herring 100 Private Companies of Asia. CapitalBio, as the only biotech company from China in the Asia 100 list, was recognized for its innovations in the field of biochip technology and will be honored in September 5-7 at the Red Herring 100 Asia Conference in Shanghai, China.
"CapitalBio is delighted to be selected by Red Herring as one of the 100 Private Companies of Asia for 2005," said Dr. Jing Cheng, Chief Executive Officer of CapitalBio. "This selection is a further affirmation of CapitalBio's biochip technology and product commercialization strategy and implementation."
"Getting selected for the Red Herring Asia 100 list is quite an achievement," said Red Herring editor-in-chief Joel Dreyfuss. "We had many strong entries, a reflection of the depth of entrepreneurship that has taken hold in Asia."
Red Herring's editorial staff rigorously evaluated more than 500 private companies through a careful analysis of financial data and subjective criteria, including quality of management, execution of strategy, and dedication to research and development. Red Herring 100 Asia companies will be presenting their business model and strategy at the Red Herring 100 Asia Conference.
About Red Herring 100 Asia Conference
Red Herring 100 Asia Conference is an invitation-only event for CEOs, select senior executives, and Venture Capitalists. Red Herring 100 Asia will bring together executives from mostly private companies. These executives will be joined by senior executives from public companies and Venture Capitalists.
CapitaBio is a leading life science Company that develops and commercializes a broad range of products, including Biochip technology products, for drug discovery research, genomics, proteomics, bio-safety testing and clinical applications. Headquartered in Beijing, China, CapitalBio has rapidly evolved from a young innovative biochip developer into a comprehensive life science entity with five affiliates or subsidiaries: AVIVA Biosciences, a San Diego, California based company that develops and markets on-chip patch-clamp technologies for ion-channel studies for drug discovery researches; Chipscreen Biosciences, a Biotech company located in Shenzhen, China, for small molecular drug discovery and development; Wangdong Medical Equipment, one of the largest medical equipment companies in China that occupies about 70% of China's conventional X-Ray imaging market; and CapitalBio International and CapitalBio Hong Kong, two fully owned subsidiaries by CapitalBio Corporation, are based at San Diego, California and Hong Kong, China respectively. Additional information on CapitalBio can be found at www.capitalbio.com.
About Red Herring
Red Herring is the weekly magazine technology entrepreneurs, investors and industry observers read to stay ahead of the curve and to be better informed about the global marketplace. Red Herring covers technology, innovation, financial strategies, important personalities and trends that are transforming the world of business with unique insight, opinion and forward-looking analysis. Readers turn to Red Herring for knowledge to make strategic decisions, build companies and create a competitive advantage for their businesses. Red Herring articles, blogs, research and event information can be found online at www.redherring.com.
CONTACT: Yi Cao of Red Herring, +1-650-585-3524, or firstname.lastname@example.org;or David Sun, Sr. VP Marketing & Business Development of CapitalBio, China,+86-10-8072-6868, or USA, +1-805-300-5155, or USAdsun@capitalbio.com